Pasar al contenido principal

Reasoned opinion on the modification of the existing MRLs for fenpyroximate in various crops

EFSA Journal logo
Wiley Online Library

Meta data

Abstract

In accordance with Article 6 of Regulation (EC) No 396/2005, Germany, hereafter referred to as the evaluating Member State (EMS), received an application from the company Nichino Europe Co Ltd. to modify the existing MRLs for fenpyroximate in various crops. In order to accommodate for the authorized uses in European Member States, the EMS Germany proposed to raise the existing MRLs of fenpyroximate in peaches, raspberries, blackberries, peppers and beans (with pods) and to lower MRLs for citrus fruit, loquat, quinces, medlar, plums, apricots, wine grapes and strawberries. No need to modify MRLs was identified for apples, pears, tomatoes and aubergines. The EMS drafted an evaluation report according to Article 8 of Regulation (EC) No 396/2005, which was submitted to the European Commission and forwarded to EFSA. According to EFSA, the submitted residue data are sufficient to support the lowering of the existing EU MRLs for citrus fruit, pome fruit, plums, wine grapes and strawberries. The submitted residue data on raspberries, blackberries, peppers and beans (with pods) substantiate the proposal to raise the existing EU MRL. The submitted residue data on peaches, tomatoes and aubergines confirm the existing EU MRL. For apricots insufficient data were provided to support the authorized use. Based on the risk assessment results, EFSA concludes that the raising of the existing EU MRLs for fenpyroximate in raspberries, blackberries, peppers and beans (with pods) and the maintaining or lowering of the existing EU MRLs for other crops under consideration, will not result in a consumer exposure exceeding the toxicological reference values and therefore is unlikely to pose a public health concern. Data gaps regarding the lack of processing studies and rotational crop studies identified by the peer review are confirmed in the current assessment and have to be further considered in the framework of the MRL review according to Article 12 of Regulation (EC) No 396/2005.